HA injections can help your patient’s OA knee pain—but not all are created equal2-3

HA injections help treat OA of the knee through mechanical and chemical actions2-3
Previously, it was suggested that mechanical or physical actions at the joint (eg, shock absorption) are responsible for achieving the primary intended purpose of the treatment of pain in OA of the knee; however, the current scientific literature supports that the mechanisms of action of HA also include chemical actions (eg, chondroprotection, anti-inflammatory effects and cartilage matrix alterations).”3-7

– Food and Drug Administration (FDA)

The Science Behind Treatment Selection For OA Knee Pain

See what two leaders in your industry are saying about HA injections to treat OA of the knee.

Molecular Weight

Molecular weight is a key differentiator between HA injections which are classified into three groups8:
(≥3000 kDa)
an increased ability to successfully bind to CD44 receptors, resulting in anti-inflammatory effects
(1500-3000 kDa)
(≤1500 kDa)
binds suboptimally to CD44 receptors, resulting in pro-inflammatory effects
Molecular weight influences endogenous HA synthesis.
  • Intra-articular (IA) injections of high molecular weight, single-chained HA induce the body to naturally synthesize its own high molecular weight HA.2,9
  • Repeat exposure to high molecular weight HA may improve how the synovial fluid distributes throughout the knee—improving the joint’s ability to produce its own HA.9-11

Structure

Linear/Single-chained HAs12

Most closely resemble natural HA found in the knee

Help with reducing knee joint inflammation

Cross-linked HAs12,13

May use formaldehyde and vinyl sulfone during chemical modification of HA

May increase the likelihood of joint inflammation

When it comes to binding to CD44 receptors, molecular weight and structure make a difference12,14

High molecular weight linear HA exerts anti-inflammatory effects by binding to CD44 receptors and limiting cytokine production.12,14

Anti-Inflammatory12,14

High Molecular Weight Linear HA

Binds to CD44 receptors PROMOTING activation of ANTI-INFLAMMATORY cytokine production

Successfully binding to CD44 receptors helps14:

  • Reduce pain and inflammation
  • Protect cartilage
  • Create more HA which is naturally found in the body

Pro-Inflammatory12,14

Low Molecular Weight Linear HA

Binds suboptimally to CD44 receptors PROMOTING PRO-INFLAMMATORY cytokine production

FINDING THE RIGHT TREATMENT
OPTION FOR OA KNEE PAIN

When it comes to OA of the knee, the right treatment can make all
the difference. Discover how some treatment options can help your
patient’s OA knee pain in more ways than one.

Download
(English)

Download
(Spanish)

Dual-Acting Effects

Find out how EUFLEXXA may help your patients’ OA knee pain in two ways.

Discover the Effects

Efficacy

Discover how EUFLEXXA performed
across three robust clinical trials.

Explore the Results
  1. Rolling 12 month average of IQVIA claims data based on unique patients (December 2022).
  2. Altman R, et al. Anti-inflammatory effects of intra-articular hyaluronic acid: a systematic review. Cartilage. 2019;10(1):43-52.
  3. Altman RD,
    Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disor. 2015;16:321.
  4. Food and Drug Administration. Federal Register. 2018;83:242.
  5. Balazs EA, The physical properties of synovial fluid and the special role of hyaluronic acid. In: Helfet AJ. Disorders of the Knee. Pages 63–75. Philadelphia: Lippincott Company, 1974.
  6. Liao Y-H, Jones SA, Forbes B, et al. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Delivery. 2005;12:327–342. https://www.tandfonline.com/doi/full/10.1080/10717540590952555%20
  7. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther. 2003;5:54-67.
  8. Bahrami M, et al. Efficacy of single high-molecular-weight versus triple low-molecular-weight hyaluronic acid intra-articular injection among knee osteoarthritis patients. BMC Musculoskelet Disor. 2020;21:550.
  9. Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int. 1987;7:113-122.
  10. Concoff A, Sancheti P, Niazi F, Shaw P, Rosen J. The efficacy
    of multiple versus single hyaluraonic acid injections: a systematic review and meta-analysis. BMC Musculoskelet Disor.
    2017 Dec 21;18(1):542. doi:10.1186/s12891-017-1897-2
  11. Loknauth J, Driscoll KE, Bendele A, Niazi F, Liang A, Larsen CC. Viscosupplementation may preserve tibial cartilage and collagen in osteoarthritis: findings from a preclinical model
    of osteoarthritis. J Exp Orthop. May 31, 2020;7(1):39. doi:10.1186/s40634-020-00256-4
  12. Nicholls M, et al. A comparison between rheological properties of intra-articular hyaluronic acid preparations and reported human synovial fluid. Adv Ther. 2018;35:523-530.
  13. Goldberg V, Coutts R. Pseudoseptic reactions of hylan viscosupplementation. Clin Orthop. 2004;
    419:130-137.
  14. Yang C, Cao M, Liu H, et al. The high and low molecular weight forms of hyaluronan have distinct effects
    on CD44 clustering. J Biol Chem. 2012;287(51):43094-43107.

Please see Important Safety Information and Full Prescribing Information

Indication

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

Important Safety Information

  • EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.
  • EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.
  • Do not inject intravascularly due to potential for systemic adverse events.
  • The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
  • The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see full Prescribing Information

Indication

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

Important Safety Information

  • EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.
  • EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.
  • Do not inject intravascularly due to potential for systemic adverse events.
  • The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
  • The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see full Prescribing Information

The Science Behind Treatment Selection for OA Knee Pain

You have selected to go to the
healthcare professional website.

Are you a US healthcare professional?

Yes No

This website may contain links to, or be accessed from links on, other worldwide websites. Ferring does not have responsibility for or control the contents, availability, operation or performance of other websites to which this website may be linked or from which this website may be accessed.

Ferring makes no representation regarding the content of any other websites which you may access from this website.